Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Kenichi Hirabayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9516-1792; OpenAlex author ID A5063847492. Sources: OpenAlex.

Their work

Papers
16 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 16

  1. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. First author DOI 10.1016/j.pan.2025.05.006↗
  2. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peri… Co-author DOI 10.1002/ags3.12719↗
  3. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytolog… Co-author DOI 10.1002/jhbp.1356↗
  4. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  5. miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. Co-author DOI 10.1038/s41598-022-22950-2↗
  6. Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Co-author DOI 10.1038/s41598-021-86152-y↗
  7. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  8. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1136/jclinpath-2020-207002↗
  9. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
  10. Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. First author DOI 10.1111/cyt.12868↗
  11. Ganglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage. First author DOI 10.1038/s41598-019-55867-4↗
  12. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00595-017-1618-3↗
  13. Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. Co-author DOI 10.1186/s40792-018-0522-4↗
  14. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma. First author DOI 10.1136/jclinpath-2016-204028↗
  15. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis. First author DOI 10.1007/s00595-015-1126-2↗
  16. Positive Intraoperative Peritoneal Lavage Cytology is a Negative Prognostic Factor in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study. Co-author DOI 10.3389/fonc.2015.00182↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoya Nakamura · 8 shared papers, 2015–2022 · strength 0.76
  2. Aya Kawanishi · 6 shared papers, 2017–2022 · strength 0.65
  3. Toshio Nakagohri · 7 shared papers, 2015–2022 · strength 0.64
  4. Haruyoshi Tanaka · 3 shared papers, 2023–2025 · strength 0.58
  5. Tsutomu Fujii · 3 shared papers, 2023–2025 · strength 0.58
  6. Motohiro Kojima · 4 shared papers, 2020–2022 · strength 0.41
  7. Tsubasa Saika · 3 shared papers, 2020–2022 · strength 0.40
  8. Nana Kimura · 2 shared papers, 2023–2024 · strength 0.39
  9. Ayaka Itoh · 2 shared papers, 2023–2024 · strength 0.39
  10. Mina Fukasawa · 2 shared papers, 2023–2024 · strength 0.39
  11. Noriyoshi Fukushima · 3 shared papers, 2021–2025 · strength 0.38
  12. Toru Furukawa · 3 shared papers, 2021–2025 · strength 0.38
  13. Masashi Morimachi · 2 shared papers, 2021–2022 · strength 0.29
  14. Misuzu Yamada · 4 shared papers, 2015–2018 · strength 0.27
  15. Yoko Matsuda · 2 shared papers, 2020–2021 · strength 0.22
  16. Takamichi Igarashi · 1 shared paper, 2024 · strength 0.21
  17. Tetsuya Mine · 3 shared papers, 2015–2018 · strength 0.20
  18. Takashi Hatori · 1 shared paper, 2025 · strength 0.19
  19. Sohei Satoi · 1 shared paper, 2025 · strength 0.19
  20. Shinichi Egawa · 1 shared paper, 2025 · strength 0.19
  21. Yohei Masugi · 1 shared paper, 2025 · strength 0.19
  22. Yoshifumi Takeyama · 1 shared paper, 2025 · strength 0.19
  23. Yuichi Nagakawa · 1 shared paper, 2025 · strength 0.19
  24. Makoto Ueno · 1 shared paper, 2025 · strength 0.19
  25. Masaji Tani · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.